Trial reportFrontiers in nutrition2025
Predictors of suboptimal glycemic control in people with type 2 diabetes and overweight or obesity: insights from baseline analysis of a diabetes-specific meal replacement study.
Trial report in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals with obesity and type 2 diabetes (T2D) constitute a high-risk subgroup that frequently exhibits suboptimal glycemic control even under standard management strategies. This study aimed to characterize the baseline metabolic and sociodemographic profiles of participants enrolled in a randomized controlled trial evaluating the efficacy of a diabetes-specific meal replacement (DSMR), and to identify predictors of suboptimal glycemic control. Methods: A total of 156 adults with T2D and BMI ≥ 25 kg/m Results: The cohort had a mean age of 52.2 years and mean HbA1c of 8.52%, indicating suboptimal glycemic control. While no correlation was found between BMI and HbA1c, HOMA-IR and ALT were positively associated with suboptimal glycemic status. In the final regression model, HOMA-IR (OR = 1.099, Conclusion: Elevated insulin resistance and liver-related markers were independent predictors of suboptimal glycemic control. The result underscores the importance of targeting metabolic dysfunction beyond weight alone in interventions for high-risk T2D populations. These findings also support the mechanistic rationale for targeted nutrition-based strategies aimed at improving insulin sensitivity and hepatic function. Moreover, they provide valuable context for interpreting participant responses within the ongoing trial. The DSMR used in this trial may offer a viable and sustainable option to improve glycemic control among high-risk individuals with T2D. Clinical trial registration: https://www.thaiclinicaltrials.org/show/TCTR20210921004, TCTR20210921004.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.